{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:52:22Z","timestamp":1792011142198,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[1999,4,9]],"date-time":"1999-04-09T00:00:00Z","timestamp":923616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,5]]},"DOI":"10.1038\/sj.bjc.6690375","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T15:05:46Z","timestamp":1031151946000},"page":"438-443","source":"Crossref","is-referenced-by-count":64,"title":["Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study"],"prefix":"10.1038","volume":"80","author":[{"name":"for the Cooperative Group of Docetaxel for Pancreatic Cancer in Japan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,4,9]]},"reference":[{"key":"BF6690375_CR1","first-page":"221","volume":"14","author":"JL Abbruzzese","year":"1995","unstructured":"Abbruzzese, J. L., Evans, D., Gravel, D., Markowitz, A., Patt, Y. & Pazdur, R. (1995). Docetaxel (D), a potentially active agent for patients with pancreatic adenocarcinomas (PA). Proc Am Soc Clin Oncol 14: 221","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690375_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/bjc.1996.37","volume":"73","author":"I Adachi","year":"1996","unstructured":"Adachi, I., Watanabe, T., Takashima, S., Narabayashi, M., Horikoshi, N., Aoyama, H. & Taguchi, T. (1996). A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210\u2013216.","journal-title":"Br J Cancer"},{"key":"BF6690375_CR3","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery, M. C., Gu\u00e9nard, D., Gu\u00e9ritte-Voegelein, F. & Lavelle, F. (1991). Experimental antitumor activity of Taxotere (RP56976, NSC628503), a Taxol analogue. Cancer Res 51: 4845\u20134852.","journal-title":"Cancer Res"},{"key":"BF6690375_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/0959-8049(93)90062-K","volume":"29A","author":"D Bissett","year":"1993","unstructured":"Bissett, D. & Kaye, S. B. (1993). Taxol and Taxotere: current status and future prospects. Eur J Cancer 29A: 1228\u20131231.","journal-title":"Eur J Cancer"},{"key":"BF6690375_CR5","first-page":"457","volume":"14","author":"R Bruno","year":"1995","unstructured":"Bruno, R., Hille, D., Thomas, L., Riva, A. & Sheiner, L. B. (1995). Population pharmacokinetics\/pharmacodynamics (PK\/PD) of docetaxel (Taxotere) in phase II studies. Proc Am Soc Clin Oncol 14: 457","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690375_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/bjc.1994.311","volume":"70","author":"T Cerny","year":"1994","unstructured":"Cerny, T., Kaplan, S., Pavlidis, N., Sch\u00f6ffski, P., Epelbaum, R., van Meerbeek, J., Wanders, J. & Franklin, H. R., Kaye S., for the ECTG (Early Clinical Trials Group of the EORTC) (1994). Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70: 384\u2013387.","journal-title":"Br J Cancer"},{"key":"BF6690375_CR7","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes, J. E. & Pazdur, R. (1995). Docetaxel. J Clin Oncol 13: 2643\u20132655.","journal-title":"J Clin Oncol"},{"key":"BF6690375_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.1996.416","volume":"74","author":"V Dieras","year":"1996","unstructured":"Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P. & Fumoleau, P. (1996). A muticentre phase II study of docetaxel 75 mg m\u22122 as first-line chemotherapy for patients with advanced breast cancer: Report of the clinical screening group of the EORTC. Br J Cancer 74: 650\u2013656.","journal-title":"Br J Cancer"},{"key":"BF6690375_CR9","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.1995.13.12.2865","volume":"13","author":"EA Eisenhauer","year":"1995","unstructured":"Eisenhauer, E. A. (1995). Docetaxel: current status and future prospects. J Clin Oncol 13: 2865\u20132868.","journal-title":"J Clin Oncol"},{"key":"BF6690375_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming, T. R. (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143\u2013151.","journal-title":"Biometrics"},{"key":"BF6690375_CR11","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","volume":"12","author":"P Francis","year":"1994","unstructured":"Francis, P., Schneider, J., Hann, L., Balmaceda, C., Barakat, R., Phillips, M. & Hakes, T. (1994). Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301\u20132308.","journal-title":"J Clin Oncol"},{"key":"BF6690375_CR12","first-page":"56","volume":"12","author":"P Fumoleau","year":"1993","unstructured":"Fumoleau, P., Chevallier, B., Kerbrat, P., Dieras, V., Le Bail, N., Bayssas, M. & Van Glabbeke, M. (1993). First line chemotherapy with TaxotereTM (T) in advanced breast cancer (ABC): a phase II study of the EORTC clinical screening group (CSG). Proc Am Soc Clin Oncol 12: 56","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690375_CR13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/jm00107a017","volume":"34","author":"F Gu\u00e9ritte-Voegelein","year":"1991","unstructured":"Gu\u00e9ritte-Voegelein, F., Gu\u00e9nard, D., Lavelle, F., Le Goff, M. T., Mangatal, L. & Potier, P. (1991). Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34: 992\u2013998.","journal-title":"J Med Chem"},{"key":"BF6690375_CR14","unstructured":"Japan Society for Cancer Therapy (1993). Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101\u2013130."},{"key":"BF6690375_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.1996.14.5.1649","volume":"14","author":"H Kunitoh","year":"1996","unstructured":"Kunitoh, H., Watanabe, K., Onoshi, T., Furuse, K., Niitani, H. & Taguchi, T. (1996). Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese Cooperative Study. J Clin Oncol 14: 1649\u20131655.","journal-title":"J Clin Oncol"},{"key":"BF6690375_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207\u2013214.","journal-title":"Cancer"},{"key":"BF6690375_CR17","unstructured":"Ministry of Health and Welfare (1991). The Japanese guidelines for the clinical evaluation of anti-neoplastic drugs. Mikusu, Tokyo"},{"key":"BF6690375_CR18","first-page":"200","volume":"13","author":"P Rougie","year":"1994","unstructured":"Rougie, P., De Forni, M., Adenis, A., Ducreux, M., Djazouli, K., Adams, D., Bonneterre, J., Clouet, P., Blanc, C., Bayssas, M. & Armand, J. P. (1994). Phase II study of Taxotere (RP56976, docetaxel) in pancreatic adenocarcinoma (PAC). Proc Am Soc Clin Oncol 13: 200","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690375_CR19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky, E. K. & Donehower, R. C. (1995). Paclitaxel (Taxol). N Engl J Med 332: 1004\u20131014.","journal-title":"N Engl J Med"},{"key":"BF6690375_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff, P. B., Fant, J. & Horwitz, S. B. (1979). Promotion of microtubule assembly in vitro by Taxol. Nature 277: 665\u2013667.","journal-title":"Nature"},{"key":"BF6690375_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10: 1\u201310.","journal-title":"Controlled Clinical Trials"},{"key":"BF6690375_CR22","first-page":"1997","volume":"21","author":"T Taguchi","year":"1994","unstructured":"Taguchi, T., Furue, H., Niitani, H., Ishitani, K., Kanamaru, R., Hasegawa, K., Ariyoshi, Y., Noda, K., Furuse, K., Fukuoka, M., Yakushiji, M. & Kashimura, M. (1994). Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug (in Japanese, abstract in English). Jpn J Cancer Chemother 21: 1997\u20132005.","journal-title":"Jpn J Cancer Chemother"},{"key":"BF6690375_CR23","first-page":"479","volume":"15","author":"Y Tanigawara","year":"1996","unstructured":"Tanigawara, Y., Sasaki, Y., Otsu, T., Fujii, H., Kashimura, M., Sasaki, T., Okumura, K. & Taguchi, T. (1996). Population pharmacokinetics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 15: 479","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690375","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:52:57Z","timestamp":1684414377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4,9]]},"references-count":23,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["BF6690375"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690375","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4,9]]}}}